Alzheon launches and gets license to Bellus Health's drug discoveries
Lexington, Mass.-based Alzheon Inc, a clinical-stage biopharmaceutical startup focused on brain health, memory and aging, has been launched with the support of unidentified private investors. The company concurrently announced the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug development platform of chemotypes and clinical datasets developed by Laval, Québec-based Bellus Health Inc. Bellus has a history of venture capital investment, and is currently backed by Power Corp's Victoria Square Ventures and other investors.
24 October 2013•5 mins read
